The global Implantable Electromechanical Ventricular Assist Device market size is predicted to grow from US$ 2885 million in 2025 to US$ 5832 million in 2031; it is expected to grow at a CAGR of 12.4% from 2025 to 2031.

A ventricular assist device (VAD) is an electromechanical device for assisting cardiac circulation, which is used either to partially or to completely replace the function of a failing heart. The function of VADs is different from that of artificial cardiac pacemakers; some are for short-term use, typically for patients recovering from myocardial infarction (heart attack) and for patients recovering from cardiac surgery; some are for long-term use (months to years to perpetuity), typically for patients suffering from advanced heart failure.

Key Features:

• Market growth prediction from 2885 million in 2025 to 5832 million in 2031
• CAGR of 12.4% from 2025 to 2031
• Key players in the market

Segmentation by Type:

• LVADs
• RVADs

Segmentation by Application:

• Bridge-to-transplant (BTT)
• Destination Therapy (DT)
• Others

Market by Region:

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Companies Coverage:

• AbioMed
• Abbott (Thoratec)
• Medtronic (HeartWare)
• Berlin Heart
• Jarvik Heart
• Sun Medical Technology Research
• ReliantHeart

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Implantable Electromechanical Ventricular Assist Device market?
2. What factors are driving Implantable Electromechanical Ventricular Assist Device market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Implantable Electromechanical Ventricular Assist Device market opportunities vary by end market size?
5. How does Implantable Electromechanical Ventricular Assist Device break out by Type, by Application?